{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:53:35Z","timestamp":1790391215814,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T00:00:00Z","timestamp":1571356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.ejca.2019.10.002","type":"journal-article","created":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T12:27:24Z","timestamp":1572870444000},"page":"138-145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma"],"prefix":"10.1016","volume":"123","author":[{"given":"Ricard","family":"Mesia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0135-0224","authenticated-orcid":false,"given":"Paolo","family":"Bossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron R.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Yun","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa F.","family":"Licitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eng-Huat","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JulieAnn","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian L.","family":"Siu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert I.","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2019.10.002_bib1","unstructured":"American Cancer Society. Global cancer facts & figures. 4th ed. https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/global-cancer-facts-and-figures\/global-cancer-facts-and-figures-4th-edition.pdf. Accessed April 29, 2019."},{"issue":"1","key":"10.1016\/j.ejca.2019.10.002_bib2","article-title":"Nasopharyngeal cancer in the world: epidemiology, incidence, mortality, and risk factors","volume":"5","author":"Salehiniya","year":"2018","journal-title":"WCRJ"},{"key":"10.1016\/j.ejca.2019.10.002_bib3","author":"American Cancer Society"},{"issue":"1","key":"10.1016\/j.ejca.2019.10.002_bib4","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s12094-017-1777-0","article-title":"SEOM clinical guideline in nasopharynx cancer (2017)","volume":"20","author":"Pastor","year":"2018","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2019.10.002_bib5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.21037\/cco.2016.03.12","article-title":"Clinical trials in nasopharyngeal carcinoma\u2014past, present and future","volume":"5","author":"Xu","year":"2016","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.ejca.2019.10.002_bib6","author":"Ministry of Health Malaysia"},{"key":"10.1016\/j.ejca.2019.10.002_bib7","series-title":"Special section: rare cancers in adults","author":"American Cancer Society","year":"2017"},{"issue":"15","key":"10.1016\/j.ejca.2019.10.002_bib8","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.ejca.2015.07.043","article-title":"Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: the EUROCARE-5 population-based study","volume":"51","author":"Gatta","year":"2015","journal-title":"Eur J Cancer"},{"issue":"29","key":"10.1016\/j.ejca.2019.10.002_bib9","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1200\/JCO.2015.60.9347","article-title":"Management of nasopharyngeal carcinoma: current practice and future perspective","volume":"33","author":"Lee","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2019.10.002_bib10","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/hed.21884","article-title":"Phase II trial of capecitabine plus cisplatin as first-line therapy in patients with metastatic nasopharyngeal cancer","volume":"34","author":"Chua","year":"2012","journal-title":"Head Neck"},{"issue":"2","key":"10.1016\/j.ejca.2019.10.002_bib11","first-page":"235","article-title":"Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma","volume":"10","author":"Tan","year":"1999","journal-title":"Ann\u00a0Oncol"},{"issue":"10054","key":"10.1016\/j.ejca.2019.10.002_bib12","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/S0140-6736(16)31388-5","article-title":"Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial","volume":"388","author":"Zhang","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2019.10.002_bib13","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Head and Neck Cancers. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/head-and-neck.pdf, version 1, Accessed 29 April 2019."},{"issue":"29","key":"10.1016\/j.ejca.2019.10.002_bib14","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1200\/JCO.2015.60.7846","article-title":"Nasopharyngeal cancer: molecular landscape","volume":"33","author":"Bruce","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2019.10.002_bib15","first-page":"131","article-title":"Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma","volume":"8","author":"Kwong","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.ejca.2019.10.002_bib16","first-page":"3877","article-title":"High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma","volume":"61","author":"Lo","year":"2001","journal-title":"Cancer Res"},{"issue":"31","key":"10.1016\/j.ejca.2019.10.002_bib17","doi-asserted-by":"crossref","first-page":"31493","DOI":"10.18632\/oncotarget.5154","article-title":"Integrin \u03b19 gene promoter is hypermethylated and downregulated in nasopharyngeal carcinoma","volume":"6","author":"Nawaz","year":"2015","journal-title":"Oncotarget"},{"issue":"17","key":"10.1016\/j.ejca.2019.10.002_bib18","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1158\/1078-0432.CCR-17-3716","article-title":"Phase I study of CC-486 alone and in combination with carboplatin or nab-paclitaxel in patients with relapsed or refractory solid tumors","volume":"24","author":"Von Hoff","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2019.10.002_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Contr Clin Trials"},{"issue":"12","key":"10.1016\/j.ejca.2019.10.002_bib20","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1038\/leu.2017.159","article-title":"A phase 1b\/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with 30% blasts","volume":"31","author":"Garcia-Manero","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2019.10.002_bib21","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.leukres.2018.08.001","article-title":"CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia","volume":"72","author":"Garcia-Manero","year":"2018","journal-title":"Leuk Res"},{"key":"10.1016\/j.ejca.2019.10.002_bib22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2147\/CIA.S24659","article-title":"Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome","volume":"7","author":"Ritchie","year":"2012","journal-title":"Clin Interv Aging"},{"issue":"7","key":"10.1016\/j.ejca.2019.10.002_bib23","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1182\/blood-2007-03-078576","article-title":"Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome","volume":"110","author":"Soriano","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ejca.2019.10.002_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0093273","article-title":"5-Azacytidine enhances the radiosensitivity of CNE2 and SUNE1 cells in\u00a0vitro and in\u00a0vivo possibly by altering DNA methylation","volume":"9","author":"Jiang","year":"2014","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.ejca.2019.10.002_bib25","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1158\/1535-7163.MCT-14-0317","article-title":"Involvement of microRNA-24 and DNA methylation in resistance of nasopharyngeal carcinoma to ionizing radiation","volume":"13","author":"Wang","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"10.1016\/j.ejca.2019.10.002_bib26","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1158\/1535-7163.MCT-15-0260","article-title":"Genome-wide identification of a methylation gene panel as a prognostic biomarker in nasopharyngeal carcinoma","volume":"14","author":"Jiang","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.ejca.2019.10.002_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.ejca.2019.10.002_bib28","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/annonc\/mdr134","article-title":"T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results","volume":"23","author":"Secondino","year":"2012","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.ejca.2019.10.002_bib29","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1002\/cncr.30541","article-title":"Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma","volume":"123","author":"Huang","year":"2017","journal-title":"Cancer"},{"issue":"36","key":"10.1016\/j.ejca.2019.10.002_bib30","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1200\/JCO.2017.73.3675","article-title":"Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study","volume":"35","author":"Hsu","year":"2017","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.ejca.2019.10.002_bib31","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2017.77.0388","article-title":"Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the Mayo Clinic Phase 2 Consortium (NCI-9742)","volume":"36","author":"Ma","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2019.10.002_bib32","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S1470-2045(18)30495-9","article-title":"Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials","volume":"19","author":"Fang","year":"2018","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491930749X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491930749X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:26:01Z","timestamp":1760732761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980491930749X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":32,"alternative-id":["S095980491930749X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2019.10.002","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2019.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}